logo

FDA Calendar

Share
Company Name Roche Holding AG
Drug Name Risdiplam (NDA)
Event Name FDA decision on Risdiplam for spinal muscular atrophy
Event Date 08/24/2020
Outcome Date
Outcome
Drug Status Priority review; Risdiplam was initially developed by PTC Therapeutics in partnership with the SMA Foundation in 2006. In November 2011, Roche gained an exclusive worldwide license Risdiplam
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar